Prescription patterns of sacubitril/valsartan among patients with hypertension in Japan

• by Aya F. Ozaki, Hisanaga Nomura, Tomohiro Terada, Eri T. Kato, Ali A. Naqvi, Julie T. Nguyen, Yuki Kunitsu

• July 17, 2026

Analysis of epicardial adipose tissue in relation to arterial hypertension using radiomics in photon-counting CT

• by Felix Waßmer, Jannik Barz, Dominik Nörenberg, Stefan O. Schoenberg, Alexander Hertel, Isabelle Ayx

• July 15, 2026

Micromegaly: a distinct clinical entity? Insights from a monocentric cohort study

• by Alessandra Mangone, Giulia Carosi, Elisa Sala, Giusy Marra, Giulia Del Sindaco, Roberta Mungari, Arianna Cremaschi, Veronica Lotito, Erika Peverelli, Emanuele Ferrante, Giovanna Mantovani

• July 20, 2026

Oral Aleniglipron Reduced Weight at 36 Weeks

In a phase 2b trial, the highest dose produced an estimated 12% mean weight reduction vs 1% with placebo, although gastrointestinal adverse events were common.

• by Kathryn Wighton

• July 16, 2026

• 6 min